


IHVR-17028

| | | | |
|---------------------------|---|-------|----------|
| Cat. No.: | HY-139663 | | |
| CAS No.: | 1428247-78-2 | | |
| Molecular Formula: | C ₂₃ H ₄₄ N ₂ O ₅ | | |
| Molecular Weight: | 429 | | |
| Target: | Glucosidase | | |
| Pathway: | Metabolic Enzyme/Protease | | |
| Storage: | Pure form | -20°C | 3 years |
| | In solvent | -80°C | 6 months |
| | | -20°C | 1 month |



BIOLOGICAL ACTIVITY

| | | | | | | | | | |
|--------------------|--|---------------|--|---------|----------|-----------------|---|---------|---|
| Description | IHVR-17028 is a potent and broad-spectrum antiviral agent. IHVR-17028 exhibits antiviral activity against BVDV, TCRV and DENV with EC ₅₀ values of 0.4 μM, 0.26 μM, 0.3 μM, respectively. IHVR-17028 is a potent ER α-glucosidase I inhibitor with an IC ₅₀ of 0.24 μM. IHVR-17028 can be used for infectious diseases research ^{[1][2]} . | | | | | | | | |
| In Vitro | In virus yield reduction assays, IHVR-17028 inhibits viral activities with EC ₅₀ values of 0.4 μM, 0.26 μM, 0.3 μM for bovine viral diarrhea virus (BVDV) (NADL strain), tacaribe virus (TCRV) (11573 strain), DENV (serotype 2, New Guinea C), respectively. And in MTT assays, IHVR-17028 exhibits IC ₅₀ values of all >500 μM in MDBK, Huh7.5 or BHK cells ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. | | | | | | | | |
| In Vivo | In Pharmacokinetic analysis in rats, IHVR17028 (oral gavage; 75 mg/kg) shows a C _{max} value of 0.18 μg/ml; the T _{max} value is 1.56 hours; and the F% value is 12% after PO administration, the T _{1/2} value is 0.88 hour after iv. administration ^[1] . IHVR-17028 (oral gavage; 25-50 mg/kg; treatment 1 day prior to virus challenging) exhibits significant protection in mouse model of lethal MARV infection ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. | | | | | | | | |
| | <table border="1"> <tr> <td>Animal Model:</td> <td>BALB/c mice are challenged with 1,000 PFU mouse adapted MARV via IP injection^[1]</td> </tr> <tr> <td>Dosage:</td> <td>50 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Treatment 1 day prior to virus challenging</td> </tr> <tr> <td>Result:</td> <td>Exhibited protection in mouse when the treatment is initiated 1 day prior to virus challenging.</td> </tr> </table> | Animal Model: | BALB/c mice are challenged with 1,000 PFU mouse adapted MARV via IP injection ^[1] | Dosage: | 50 mg/kg | Administration: | Treatment 1 day prior to virus challenging | Result: | Exhibited protection in mouse when the treatment is initiated 1 day prior to virus challenging. |
| Animal Model: | BALB/c mice are challenged with 1,000 PFU mouse adapted MARV via IP injection ^[1] | | | | | | | | |
| Dosage: | 50 mg/kg | | | | | | | | |
| Administration: | Treatment 1 day prior to virus challenging | | | | | | | | |
| Result: | Exhibited protection in mouse when the treatment is initiated 1 day prior to virus challenging. | | | | | | | | |
| | <table border="1"> <tr> <td>Animal Model:</td> <td>C57B1/6 mice challenged with 1,000 PFU mouse adapted EBOV^[1]</td> </tr> <tr> <td>Dosage:</td> <td>25 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Twice daily at 12 h interval; starting 4 h post infection for 10 days</td> </tr> <tr> <td>Result:</td> <td>Inhibited EBOV infection in mice.</td> </tr> </table> | Animal Model: | C57B1/6 mice challenged with 1,000 PFU mouse adapted EBOV ^[1] | Dosage: | 25 mg/kg | Administration: | Twice daily at 12 h interval; starting 4 h post infection for 10 days | Result: | Inhibited EBOV infection in mice. |
| Animal Model: | C57B1/6 mice challenged with 1,000 PFU mouse adapted EBOV ^[1] | | | | | | | | |
| Dosage: | 25 mg/kg | | | | | | | | |
| Administration: | Twice daily at 12 h interval; starting 4 h post infection for 10 days | | | | | | | | |
| Result: | Inhibited EBOV infection in mice. | | | | | | | | |

REFERENCES

[1]. Jinhong Chang, et al. Small molecule inhibitors of ER α -glucosidases are active against multiple hemorrhagic fever viruses. *Antiviral Res.* 2013 Jun;98(3):432-40.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA